The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
IDHENTIFY phase III trial fails to meet primary end point
On August 25, 2020, it was announced that the phase III IDHENTIFY trial (NCT02577406), evaluating enasidenib plus best supportive care (BSC) versus conventional care regimens (CCR), failed to meet its primary endpoint of overall survival (OS) for elderly patients with relapsed/refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase 2 (IDH2) mutation. However, the safety profile of enasidenib was consistent with previous reports.1
IDH2 mutations affect ~19% of patients with AML, and enasidenib is the only U.S. Food and Drug Administration (FDA)-approved therapy for this group of patients with R/R disease.1
IDHENTIFY trial design2
- Phase III, open-label, multicenter, randomized trial comparing enasidenib plus BSC versus CCR
- 319 patients ≥ 60 years of age with late stage R/R IDH2-mutated AML after second- or third-line therapy recruited
- BSC included
- hydroxyurea for leukocytosis and/or differentiation-like syndrome
- anti-infectives
- analgesics
- antiemetics
- antipyretics
- transfusions
- nutritional support
- CCR included
- BSC only
- azacitidine (75 mg/m2/day subcutaneously for 7 days) plus BSC
- low-dose cytarabine (20 mg subcutaneously twice a day for 10 days) plus BSC
- intermediate-dose cytarabine (0.5–1.5 g/m2/day intravenously for 3–6 days) plus BSC
- Enasidenib: 100 mg once daily, orally, for 28-day cycles
- All therapies administered in continuous 28-day cycles
- Primary endpoint: OS
- Key secondary endpoints: Overall response rate, event-free survival, duration of response, and time to response
Enasidenib1
- Oral inhibitor of IDH2
- Approved by the FDA in 2017 for patients with R/R, IDH2-mutated AML
- Also approved in Australia and Canada for this group of patients
The results of this trial are due to be published at a future conference. For further information on enasidenib for the treatment of AML, read our collated articles here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content